Literature DB >> 6765532

Successful treatment of immune-mediated insulin resistance by human insulin (recombinant DNA).

F Maneschi, S E Fineberg, E M Kohner.   

Abstract

An 82-yr-old woman with type II diabetes developed antibody-mediated insulin resistance while on mixed pork-beef insulin concomitantly with a non-Hodgkin lymphoma. Insulin resistance was initially treated with highly purified pork insulin, but this was unsuccessful. Treatment with human insulin (recombinant DNA) was associated with marked decrease of both insulin requirement and high-affinity antibodies, increase of free insulin levels, and improvement of diabetic control. This patient's case shows that human insulin can be considered as an alternative treatment for immune-mediated insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6765532     DOI: 10.2337/diacare.5.2.s175

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

1.  Human insulin.

Authors:  J Pickup
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-18

2.  Choice of insulin.

Authors:  P J Watkins
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26

Review 3.  Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

4.  Immunogenicity of recombinant DNA human insulin.

Authors:  S E Fineberg; J A Galloway; N S Fineberg; M J Rathbun; S Hufferd
Journal:  Diabetologia       Date:  1983-12       Impact factor: 10.122

Review 5.  Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients.

Authors:  Xiaolei Hu; Fengling Chen
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.